Elevance Health, Inc. $ELV Stock Holdings Raised by Eminence Capital LP

Eminence Capital LP grew its stake in Elevance Health, Inc. (NYSE:ELV) by 32.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 487,147 shares of the company’s stock after purchasing an additional 120,358 shares during the quarter. Elevance Health makes up approximately 2.7% of Eminence Capital LP’s holdings, making the stock its 17th biggest holding. Eminence Capital LP’s holdings in Elevance Health were worth $170,769,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Evolve Private Wealth LLC acquired a new stake in Elevance Health during the fourth quarter valued at approximately $578,000. First Manhattan CO. LLC. grew its position in shares of Elevance Health by 345.5% in the 4th quarter. First Manhattan CO. LLC. now owns 18,317 shares of the company’s stock worth $6,421,000 after acquiring an additional 14,205 shares in the last quarter. Capitolis Liquid Global Markets LLC grew its position in shares of Elevance Health by 97.4% in the 4th quarter. Capitolis Liquid Global Markets LLC now owns 75,000 shares of the company’s stock worth $26,291,000 after acquiring an additional 37,000 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in shares of Elevance Health by 0.6% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 11,144 shares of the company’s stock valued at $3,908,000 after acquiring an additional 70 shares during the last quarter. Finally, Align Financial LLC acquired a new stake in shares of Elevance Health during the 4th quarter valued at approximately $369,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Trading Down 1.4%

NYSE:ELV opened at $392.04 on Thursday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The stock has a market cap of $85.13 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 2.25 and a beta of 0.67. The business has a fifty day moving average of $372.34 and a 200-day moving average of $346.21. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the business earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts predict that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is currently 29.26%.

Wall Street Analyst Weigh In

ELV has been the subject of several recent research reports. Jefferies Financial Group lowered their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Mizuho boosted their price objective on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Leerink Partners set a $364.00 target price on shares of Elevance Health in a report on Thursday, April 23rd. Finally, Robert W. Baird lifted their target price on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is owned by company insiders.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.